Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

PRICED: DOC Pharma E990m sr sec 2-part, E590m 7NC3 fixed 5.625% at 100, E400m 7NC1 FRN E+362.5bp at 100

HYC European Market: Deal Flow - General

+++Adds detail (pay dates, call dates, ISINs)+++

Dolcetto Holdco SpA (DOC Pharma) (DOLCTH) EUR990m 144A/Reg S sr sec notes 2-part. B3/B (stable/stable). Via BNP (B&D)/Barc jt glocos/DB jt physical books/IMI/Mizuho/CA/KKR jt books. No reg rights. List Lux. NY law. Settles 07/14.

- EUR590m (from EUR350m minimum) sr sec fixed-rate notes due 07/14/32 (7y). NC3 (06/25/28) (MWC B+50bp), then at 102.813, 101.406, 100. Equity claw: 3y 40% at 105.625. IPO claw: 4y 50% at 101. Special call: 10% per year the first 3 years at 103. CoC at 101. 30/360. Pays March 15 and Sept 15, starting 09/15/25 (30/360). Denoms: 100x1. Reg S ISIN: XS3106724241. IPT: high 5s-6%. Price talk: 5.75% area (+/- 12.5bp). Revised price talk: 5.625%-5.75%. Priced: 5.625% at 100. +331bp vs DBR 1.70% 08/15/32.

- EUR400m (from EUR350m minimum) sr sec FRN due 07/14/32 (7y). NC1 (06/25/26) (MWC B+50bp), then at 100. CoC at 101. Pays March 15, June 15, Sept 15 and Dec 15, starting 09/15/25 (Actual/360). Denoms: 100x1. Reg S ISIN: XS73106723516. IPT: 3mE+400bp area at par. Price talk: E+375-400bp at par. Revised price talk: E+375bp area at par. Priced: 3mE+362.5bp at 100.

Roadshow (1-on-1s) 06/23-25 (investor call at 1pm UKT 06/30). Books closed at 4:30pm UKT (from 3pm UKT) 06/25. UOP: repay $973m unitranche facility, GCP. Equity sponsors: TPG (804%), ICG (17.9%). Biz: leading Italian generic pharmaceutical company.

Deal roadshow: https://dealroadshow.com/ Entry code: DOC25.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.